Use of drug-eluting stents in acute myocardial infarction with persistent ST-segment elevation: results of the ALKK PCI-registry
详细信息 查看全文
- 作者：Tobias H?rle (1)
Uwe Zeymer (2) (3)
Arne Kristian Schwarz (1)
Claus Lüers (1)
Matthias Hochadel (3)
Harald Darius (4)
Wolfgang Kasper (5)
Karl Eugen Hauptmann (6)
Dietrich Andresen (7)
Albrecht Els?sser (1) - 关键词：Drug ; eluting stent ; Myocardial infarction ; STEMI ; Germany
- 刊名：Clinical Research in Cardiology
- 出版年：2014
- 出版时间：May 2014
- 年：2014
- 卷：103
- 期：5
- 页码：373-380
- 全文大小：318 KB
- 参考文献：1. Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, Kozuma K, Van Langenhove G, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW (2001) Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 104:2007-011 CrossRef
2. Fajadet J, Morice MC, Bode C, Barragan P, Serruys PW, Wijns W, Constantini CR, Guermonprez JL, Eltchaninoff H, Blanchard D, Bartorelli A, Laarman GJ, Perin M, Sousa JE, Schuler G, Molnar F, Guagliumi G, Colombo A, Ban Hayashi E, Wulfert E (2005) Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation 111:1040-044 CrossRef
3. Weisz G, Leon MB, Holmes DR Jr, Kereiakes DJ, Popma JJ, Teirstein PS, Cohen SA, Wang H, Cutlip DE, Moses JW (2009) Five-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. J Am Coll Cardiol 53:1488-497 CrossRef
4. Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Baldus S, Hauptmann KE, Suttorp MJ, Drzewiecki J, Pieper M, Schultheiss HP, Mauri L (2010) Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study. EuroIntervention 6:562-67 CrossRef
5. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R (2002) A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346:1773-780 CrossRef
6. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, Lopez-Sendon J, Marco J, Menicanti L, Ostojic M, Piepoli MF, Pirlet C, Pomar JL, Reifart N, Ribichini FL, Schalij MJ, Sergeant P, Serruys PW, Silber S, Sousa Uva M, Taggart D (2010) Guidelines on myocardial revascularization. Eur Heart J 31:2501-555 CrossRef
7. Silber S, Borggrefe M, Bohm M, Hoffmeister HM, Dietz R, Ertl G, Heusch G (2008) Drug-eluting coronary stents and drug eluting balloon catheters: summary of the position papers of the DGK. Clin Res Cardiol 97:548-63 CrossRef
8. Sarno G, Lagerqvist B, Frobert O, Nilsson J, Olivecrona G, Omerovic E, Saleh N, Venetzanos D, James S (2012) Lower risk of stent thrombosis and restenosis with unrestricted use of ‘new-generation-drug-eluting stents: a report from the nationwide Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 33:606-13 CrossRef
9. Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, Di Lorenzo E, Kaiser C, Tierala I, Mehilli J, Seyfarth M, Varenne O, Dirksen MT, Percoco G, Varricchio A, Pittl U, Syvanne M, Suttorp MJ, Violini R, Schomig A (2007) Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 28:2706-713 CrossRef
10. Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T, van der Wieken LR, Tijssen JG, Rensing BJ, Patterson M (2006) Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 355:1105-113 CrossRef
11. Mauri L, Silbaugh TS, Garg P, Wolf RE, Zelevinsky K, Lovett A, Varma MR, Zhou Z, Normand SL (2008) Drug-eluting or bare-metal stents for acute myocardial infarction. N Engl J Med 359:1330-342 CrossRef
12. Menichelli M, Parma A, Pucci E, Fiorilli R, De Felice F, Nazzaro M, Giulivi A, Alborino D, Azzellino A, Violini R (2007) Randomized trial of sirolimus-eluting stent versus bare-metal stent in acute myocardial infarction (SESAMI). J Am Coll Cardiol 49:1924-930 CrossRef
13. Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrie D, Slama MS, Merkely B, Erglis A, Margheri M, Varenne O, Cebrian A, Stoll HP, Snead DB, Bode C (2006) Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 355:1093-104 CrossRef
14. Vogt A, Bonzel T, Harmjanz D, von Leitner ER, Pfafferott C, Engel HJ, Niederer W, Schuster PR, Glunz HG, Neuhaus KL (1997) PTCA registry of German community hospitals. Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (ALKK) Study Group. Eur Heart J 18:1110-114 CrossRef
15. Zeymer U, Vogt A, Zahn R, Weber MA, Tebbe U, Gottwik M, Bonzel T, Senges J, Neuhaus KL (2004) Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI); results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte (ALKK). Eur Heart J 25:322-28 CrossRef
16. Zeymer U, Zahn R, Hochadel M, Bonzel T, Weber M, Gottwik M, Tebbe U, Senges J (2005) Incications and complications of invasive diagnostic procedures and percutaneous coronary interventions in the year 2003. Results of the quality control registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte (ALKK). Z Kardiol 94:392-98 CrossRef
17. Tebbe U, Hochadel M, Bramlage P, Kerber S, Hambrecht R, Grube E, Hauptmann KE, Gottwik M, Elsasser A, Glunz HG, Bonzel T, Carlsson J, Zeymer U, Zahn R, Senges J (2009) In-hospital outcomes after elective and non-elective percutaneous coronary interventions in hospitals with and without on-site cardiac surgery backup. Clin Res Cardiol 98:701-07 CrossRef
18. Dziewierz A, Siudak Z, Rakowski T, Birkemeyer R, Mielecki W, Ranosz P, Dubiel JS, Dudek D (2011) Drug-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: a mortality analysis from the EUROTRANSFER Registry. Clin Res Cardiol 100:139-45 CrossRef
19. Steg PG, Fox KA, Eagle KA, Furman M, Van de Werf F, Montalescot G, Goodman SG, Avezum A, Huang W, Gore JM (2009) Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. Eur Heart J 30:321-29 CrossRef
20. Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R (2007) Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115:1051-058 CrossRef
21. Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW, Hong MK, Kim JJ, Park SJ (2006) Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 98:352-56 CrossRef
22. Kalesan B, Pilgrim T, Heinimann K, Raber L, Stefanini GG, Valgimigli M, da Costa BR, Mach F, Luscher TF, Meier B, Windecker S, Juni P (2012) Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. Eur Heart J 33:977-87 CrossRef
23. Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, Gold HK, Burke AP, Kolodgie FD, Virmani R (2008) Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation 118:1138-145 CrossRef
24. Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C, Vogel R, Hess O, Meier B, Windecker S (2007) Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 115:2426-434 CrossRef
25. Guagliumi G, Costa MA, Sirbu V, Musumeci G, Bezerra HG, Suzuki N, Matiashvili A, Lortkipanidze N, Mihalcsik L, Trivisonno A, Valsecchi O, Mintz GS, Dressler O, Parise H, Maehara A, Cristea E, Lansky AJ, Mehran R, Stone GW (2011) Strut coverage and late malapposition with paclitaxel-eluting stents compared with bare metal stents in acute myocardial infarction: optical coherence tomography substudy of the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial. Circulation 123:274-81 CrossRef
26. Brar SS, Leon MB, Stone GW, Mehran R, Moses JW, Brar SK, Dangas G (2009) Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. J Am Coll Cardiol 53:1677-689 CrossRef
27. Dibra A, Tiroch K, Schulz S, Kelbaek H, Spaulding C, Laarman GJ, Valgimigli M, Di Lorenzo E, Kaiser C, Tierala I, Mehilli J, Campo G, Thuesen L, Vink MA, Schalij MJ, Violini R, Schomig A, Kastrati A (2010) Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. Clin Res Cardiol 99:345-57 CrossRef
28. Piccolo R, Cassese S, Galasso G, Niglio T, De Rosa R, De Biase C, Piscione F (2012) Long-term clinical outcomes following sirolimus-eluting stent implantation in patients with acute myocardial infarction. A meta-analysis of randomized trials. Clin Res Cardiol 101:885-93 CrossRef
29. Stone GW, Lansky AJ, Pocock SJ, Gersh BJ, Dangas G, Wong SC, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Mockel M, Ochala A, Kellock A, Parise H, Mehran R (2009) Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 360:1946-959 CrossRef
30. Tentzeris I, Jarai R, Farhan S, Wojta J, Schillinger M, Geppert A, Nurnberg M, Unger G, Huber K (2011) Long-term outcome after drug-eluting stent implantation in comparison with bare metal stents: a single centre experience. Clin Res Cardiol 100:191-00 CrossRef
31. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ (2010) Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 362:1663-674 CrossRef
32. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, Smits PC (2010) Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 375:201-09 CrossRef
33. Park DW, Kim YH, Yun SC, Kang SJ, Lee SW, Lee CW, Park SW, Seong IW, Lee JH, Tahk SJ, Jeong MH, Jang Y, Cheong SS, Yang JY, Lim DS, Seung KB, Chae JK, Hur SH, Lee SG, Yoon J, Lee NH, Choi YJ, Kim HS, Kim KS, Hong TJ, Park HS, Park SJ (2010) Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. J Am Coll Cardiol 56:1187-195 CrossRef
34. de Waha A, Cassese S, Park DW, Burzotta F, Byrne RA, Tada T, King LA, Park SJ, Schomig A, Kastrati A (2012) Everolimus-eluting versus sirolimus-eluting stents: an updated meta-analysis of randomized trials. Clin Res Cardiol 101:461-67 CrossRef
35. Bangalore S, Amoroso N, Fusaro M, Kumar S, Feit F (2013) Outcomes with various drug-eluting or bare metal stents in patients with st-segment-elevation myocardial infarction: a mixed treatment comparison analysis of trial level data from 34 068 patient-years of follow-up from randomized trials. Circ Cardiovasc Interv 6:378-90 CrossRef
36. Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabate M, Valgimigli M, Frati G, Kedhi E, Smits PC, Kaiser C, Genereux P, Galatius S, Kirtane AJ, Stone GW (2013) Clinical outcomes with drug-eluting and bare-metal stents in patients with ST-segment elevation myocardial infarction: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 62:496-04 CrossRef
37. Steg PG, James SK, Atar D, Badano LP, Lundqvist CB, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, Van’t Hof A, Widimsky P, Zahger D, Bax JJ, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Kirchhof P, Kolh P, McDonagh T, Moulin C, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian A, Windecker S, Astin F, Astrom-Olsson K, Budaj A, Clemmensen P, Collet JP, Fox KA, Fuat A, Gustiene O, Hamm CW, Kala P, Lancellotti P, Maggioni AP, Merkely B, Neumann FJ, Piepoli MF, Van de Werf F, Verheugt F, Wallentin L (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 33:2569-619 CrossRef
38. Pfisterer M, Brunner-La Rocca HP, Rickenbacher P, Hunziker P, Mueller C, Nietlispach F, Leibundgut G, Bader F, Kaiser C (2009) Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. Eur Heart J 30:16-4 CrossRef
39. Sobel BE (2001) Acceleration of restenosis by diabetes: pathogenetic implications. Circulation 103:1185-187 CrossRef
40. Erglis A, Narbute I, Kumsars I, Jegere S, Mintale I, Zakke I, Strazdins U, Saltups A (2007) A randomized comparison of paclitaxel-eluting stents versus bare-metal stents for treatment of unprotected left main coronary artery stenosis. J Am Coll Cardiol 50:491-97 CrossRef
41. Scheller B, Levenson B, Joner M, Zahn R, Klauss V, Naber C, Sch?chinger V, Els?sser A (2011) Medikamente freisetzende Koronarstents und mit Medikamenten beschichtete Ballonkatheter—Positionspapier der DGK 2011. Der Kardiologe 5:411-35 CrossRef
42. de Waha A, Dibra A, Kufner S, Baumgart D, Sabate M, Maresta A, Schomig A, Kastrati A (2011) Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with diabetes mellitus: a patient-level meta-analysis of randomized trials. Clin Res Cardiol 100:561-70 CrossRef - 作者单位：Tobias H?rle (1)
Uwe Zeymer (2) (3)
Arne Kristian Schwarz (1)
Claus Lüers (1)
Matthias Hochadel (3)
Harald Darius (4)
Wolfgang Kasper (5)
Karl Eugen Hauptmann (6)
Dietrich Andresen (7)
Albrecht Els?sser (1)
1. Klinikum Oldenburg, Klinik für Kardiologie, Rahel-Straus-Str. 10, 26133, Oldenburg, Germany
2. Klinikum Ludwigshafen, Medizinische Klinik B, Ludwigshafen, Germany
3. Stiftung Institut für Herzinfarktforschung, Ludwigshafen, Germany
4. Vivantes Klinikum Neuk?lln, Klinik für Kardiologie, Angiologie und Intensivmedizin, Berlin, Germany
5. St. Josefs-Hospital, Medizinische Klinik I, Wiesbaden, Germany
6. Krankenhaus der Barmherzigen Brüder, Abteilung für Kardiologie, Trier, Germany
7. Vivantes Klinikum Am Urban/Im Friedrichshain, Abteilung für Kardiologie, Berlin, Germany - ISSN：1861-0692
文摘
Background Drug-eluting stents (DES) reduce the rate of in-stent restenosis (ISR) and target vessel revascularization significantly when compared with bare metal stents (BMS). Their beneficial effects have been demonstrated in patients with acute myocardial infarction also, but the use of DES in the latter population seems to be still limited in clinical practice. Methods and results From January 2006 to December 2011, 25,424 patients with ST-elevation myocardial infarction were enrolled in the German ALKK PCI-registry. In 5,467 patients (21.5?%), a DES was implanted in the culprit segment, in 16,911 patients (66.5?%) a BMS, and 2,959 patients (11.6?%) received neither DES nor BMS. The rates of DES for typical subgroups were 31.7?% in patients with diabetes, 36.6?% in unprotected left main stenosis, 32.4?% in ostial lesions, 32.0?% for a stent length >15?mm, 26.2?% for a stent diameter ??mm, and 58.5?% for ISR. There was a wide range in the use of DES between the different ALKK hospitals with a minimum of 2.3?% and a maximum of 58.3?% for the total study period (median 22.0?%, quartiles 14.6 and 37.5?%). Conclusions Despite convincing data for the use of DES in patients with STEMI, there is still an underuse of DES in this clinical setting in Germany. This is particularly worrying for the subgroups of patients and lesions with a high risk of restenosis. Further efforts are needed to reduce the skepticism about DES and to improve guideline adherent treatment.